Ulrich Kintscher

Ulrich Kintscher

Auto-generated profile, based on publicly available information

Ulrich Kintscher

Charité - Universitätsmedizin Berlin, Institute of Pharmacology , Hessische Str. 3-4, 10115 Berlin

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2018 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
VRVera Regitz-Zagrosek
Vera Regitz-Zagrosek
JRJolien W. Roos-Hesselink
Jolien W. Roos-Hesselink
JBJohann Bauersachs
Johann Bauersachs
CBCarina Blomström-Lundqvist
Carina Blomström-Lundqvist
RCRenata Cífková
Renata Cífková
CNCatherine Nelson-Piercy
Catherine Nelson-Piercy
The Task Force for the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)

10 February 2005 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
DDDuska Dragun
Duska Dragun
DMDominik Muller
Dominik Muller
JBJan Hinrich Bräsen
Jan Hinrich Bräsen
LFLutz Fritsche
Lutz Fritsche
MNMelina Nieminen-Kelhä
Melina Nieminen-Kelhä
GWGerd Wallukat
Gerd Wallukat
Antibodies against HLA antigens cause refractory allograft rejection with vasculopathy in some, but not all, patients. We studied 33 kidney-transplant recipients who had refractory vascular rejection. Thirteen had donor-specific anti-HLA antibodies, whereas 20 did not. Malignant hypertension was present in 16 of the patients without anti-HLA antibodies, 4 of whom had seizures. The remaining 17 patients had no malignant hypertension. We hypothesized that activating antibodies targeting the angiotensin II type 1 (AT1) receptor might be involved. Activating IgG antibodies targeting the AT1 receptor were detected in serum from all 16 patients with malignant hypertension and without anti-HLA antibodies, but in no other patients. These receptor-activating antibodies are subclass IgG1 and IgG3 antibodies that bind to two different epitopes on the second extracellular loop of the AT1 receptor. Tissue factor expression was increased in renal-biopsy specimens from patients with these antibodies. In vitro stimulation of vascular cells with an AT1-receptor–activating antibody induced phosphorylation of ERK 1/2 kinase and increased the DNA binding activity of the transcription factors activator protein 1 (AP-1) and nuclear factor-κB. The AT1 antagonist losartan blocked agonistic AT1-receptor antibody–mediated effects, and passive antibody transfer induced vasculopathy and hypertension in a rat kidney-transplantation model. A non-HLA, AT1-receptor–mediated pathway may contribute to refractory vascular rejection, and affected patients might benefit from removal of AT1-receptor antibodies or from pharmacologic blockade of AT1 receptors.

1 July 2008 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
UKUlrich Kintscher
Ulrich Kintscher
MHMartin Hartge
Martin Hartge
KHKatharina Hess
Katharina Hess
AFAnna Foryst-Ludwig
Anna Foryst-Ludwig
MCMarkus Clemenz
Markus Clemenz
NMNikolaus Marx
Nikolaus Marx
Background— Adipose tissue inflammation may play a critical role in the pathogenesis of insulin resistance (IR). The present study examined the role of lymphocytes in adipose tissue inflammation and IR. Methods and Results— In a mouse model of obesity-mediated IR, high-fat diet (HFD) induced IR already after 5 weeks, which was associated with a marked T-lymphocyte infiltration in visceral adipose tissue. In contrast, recruitment of macrophages was delayed with an increase of MAC3-positive staining and F4/80 mRNA expression after 10 weeks of HFD, suggesting a dissociation of macrophage invasion into adipose tissue and IR initiation. In patients with type 2 diabetes, lymphocyte content in adipose tissue biopsies significantly correlated with waist circumference, a marker of IR. Immunohistochemical staining of human adipose tissue revealed the presence of mainly CD4-positive lymphocytes as well as macrophage infiltration. Most macrophages were HLA-DR–positive, reflecting activation through IFNγ, a cytokine released from CD4-positive lymphocytes. Conclusions— Proinflammatory T-lymphocytes are present in visceral adipose tissue and may contribute to local inflammatory cell activation before the appearance of macrophages, suggesting that these cells could play an important role in the initiation and perpetuation of adipose tissue inflammation as well as the development of IR.

3 November 2015 in European Heart Journal
Verified
Journal Article
Open access
PDF file
VRVera Regitz-Zagrosek
Vera Regitz-Zagrosek
Sabine Oertelt-PrigioneSabine Oertelt-Prigione
Sabine Oertelt-Prigione
EPEva Prescott
Eva Prescott
FFFlavia Franconi
Flavia Franconi
EGEva Gerdts
Eva Gerdts
VSVerena Stangl
Verena Stangl
In the vast majority of cardiovascular diseases (CVDs), there are well-described differences between women and men in epidemiology, pathophysiology, clinical manifestations, effects of therapy, and outcomes.1–3 These differences arise on one hand from biological differences among women and men, which are called sex differences. They are due to differences in gene expression from the sex chromosomes and subsequent differences in sexual hormones leading to differences in gene expression and function in the CV system, e.g. in vascular function and NO signalling, in myocardial remodelling under stress, or metabolism of drugs by sex-specific cytochrome expression. Sex differences are frequently reproducible in animal models. In contrast, gender differences are unique to the human. They arise from sociocultural processes, such as different behaviours of women and men; exposure to specific influences of the environment; different forms of nutrition, lifestyle, or stress; or attitudes towards treatments and prevention. These are equally important for CVDs. Both sex and gender (S&G) influence human development (Figure 1). Since it is almost impossible to distinguish properly between effects of S&G in the medical field, the EUGenMed writing group decided to discuss both of them together and to use the term S&G for all medical relevant differences between women and men in the present review.

4 May 2004 in Circulation
Verified
Journal Article
Closed access
PDF file
MSMichael Schupp
Michael Schupp
JJJürGen Janke
JürGen Janke
RCRonald Clasen
Ronald Clasen
TUThomas Unger
Thomas Unger
UKUlrich Kintscher
Ulrich Kintscher
Background— Angiotensin type 1 receptor (AT 1 R) blockers (ARB) have been shown to reduce the incidence of type 2 diabetes mellitus by an unknown molecular mechanism. The peroxisome proliferator–activated receptor-γ (PPARγ) is the central regulator of insulin and glucose metabolism improving insulin sensitivity. We investigated the regulation of PPARγ function by ARBs. Methods and Results— The ARBs irbesartan and telmisartan (10 μmol/L) potently enhanced PPARγ-dependent 3T3-L1 adipocyte differentiation associated with a significant increase in mRNA expression of the adipogenic marker gene adipose protein 2 (aP2), as measured by quantitative real-time polymerase chain reaction (irbesartan: 3.3±0.1-fold induction; telmisartan: 3.1±0.3-fold induction; both P <0.01). Telmisartan showed a more pronounced induction of aP2 expression in lower, pharmacologically relevant concentrations compared with the other ARBs. The ARB losartan enhanced aP2 expression only at high concentrations (losartan 100 μmol/L: 3.6±0.3-fold induction; P <0.01), whereas eprosartan up to 100 μmol/L had no significant effects. In transcription reporter assays, irbesartan and telmisartan (10 μmol/L) markedly induced transcriptional activity of PPARγ by 3.4±0.9-fold and 2.6±0.6-fold ( P <0.05), respectively, compared with 5.2±1.1-fold stimulation by the PPARγ ligand pioglitazone (10 μmol/L). Irbesartan and telmisartan also induced PPARγ activity in an AT 1 R-deficient cell model (PC12W), demonstrating that these ARBs stimulate PPARγ activity independent of their AT 1 R blocking actions. Conclusions— The present study demonstrates that a specific subset of ARBs induces PPARγ activity, thereby promoting PPARγ-dependent differentiation in adipocytes. The activation of PPARγ demonstrates new pleiotropic actions of certain ARBs, providing a potential mechanism for their insulin-sensitizing/antidiabetic effects.

1 March 2001 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
ACAlan R. Collins
Alan R. Collins
WMWoerner P. Meehan
Woerner P. Meehan
UKUlrich Kintscher
Ulrich Kintscher
SJSimon Jackson
Simon Jackson
SWShu Wakino
Shu Wakino
RLRonald E. Law
Ronald E. Law
—Peroxisome proliferator–activated receptor-γ (PPARγ) is a ligand-activated nuclear receptor expressed in all of the major cell types found in atherosclerotic lesions: monocytes/macrophages, endothelial cells, and smooth muscle cells. In vitro, PPARγ ligands inhibit cell proliferation and migration, 2 processes critical for vascular lesion formation. In contrast to these putative antiatherogenic activities, PPARγ has been shown in vitro to upregulate the CD36 scavenger receptor, which could promote foam cell formation. Thus, it is unclear what impact PPARγ activation will have on the development and progression of atherosclerosis. This issue is important because thiazolidinediones, which are ligands for PPARγ, have recently been approved for the treatment of type 2 diabetes, a state of accelerated atherosclerosis. We report herein that the PPARγ ligand, troglitazone, inhibited lesion formation in male low density lipoprotein receptor–deficient mice fed either a high-fat diet, which also induces type 2 diabetes, or a high-fructose diet. Troglitazone decreased the accumulation of macrophages in intimal xanthomas, consistent with our in vitro observation that troglitazone and another thiazolidinedione, rosiglitazone, inhibited monocyte chemoattractant protein-1–directed transendothelial migration of monocytes. Although troglitazone had some beneficial effects on metabolic risk factors (in particular, a reduction of insulin levels in the diabetic model), none of the systemic cardiovascular risk factors was consistently improved in either model. These observations suggest that the inhibition of early atherosclerotic lesion formation by troglitazone may result, at least in part, from direct effects of PPARγ activation in the artery wall.